# A Study of JSKN027 in Patients With Advanced Solid Tumors

> **NCT07391644** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 250 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor

## Interventions

- **DRUG:** JSKN027

## Key facts

- **NCT ID:** NCT07391644
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-15
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07391644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07391644, "A Study of JSKN027 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07391644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*